WO2026042012A1 - Anticorps à domaine unique et polypeptides les contenant - Google Patents

Anticorps à domaine unique et polypeptides les contenant

Info

Publication number
WO2026042012A1
WO2026042012A1 PCT/IB2025/058370 IB2025058370W WO2026042012A1 WO 2026042012 A1 WO2026042012 A1 WO 2026042012A1 IB 2025058370 W IB2025058370 W IB 2025058370W WO 2026042012 A1 WO2026042012 A1 WO 2026042012A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
variant
acid sequence
acid substitutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2025/058370
Other languages
English (en)
Inventor
Simon Theodor HANSEN
Botond Miklós Roska
Temurkhan AYUPOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Molecular And Clinical Ophthalmology Basel Iob
Original Assignee
Institute Of Molecular And Clinical Ophthalmology Basel Iob
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Molecular And Clinical Ophthalmology Basel Iob filed Critical Institute Of Molecular And Clinical Ophthalmology Basel Iob
Publication of WO2026042012A1 publication Critical patent/WO2026042012A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps à domaine unique (sdAb) qui ont une spécificité de liaison pour CD71, CD73, CD142, TOMM20 et TOMM70 comprenant une CDR1, CDR2 et une CDR3. L'invention concerne également des protéines de fusion, des formats d'immunoglobuline et des conjugués comprenant le sdAb.
PCT/IB2025/058370 2024-08-19 2025-08-18 Anticorps à domaine unique et polypeptides les contenant Pending WO2026042012A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463684592P 2024-08-19 2024-08-19
US63/684,592 2024-08-19
US202463711933P 2024-10-25 2024-10-25
US63/711,933 2024-10-25

Publications (1)

Publication Number Publication Date
WO2026042012A1 true WO2026042012A1 (fr) 2026-02-26

Family

ID=97026404

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2025/058371 Pending WO2026042013A1 (fr) 2024-08-19 2025-08-18 Thérapie mitochondriale
PCT/IB2025/058370 Pending WO2026042012A1 (fr) 2024-08-19 2025-08-18 Anticorps à domaine unique et polypeptides les contenant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2025/058371 Pending WO2026042013A1 (fr) 2024-08-19 2025-08-18 Thérapie mitochondriale

Country Status (1)

Country Link
WO (2) WO2026042013A1 (fr)

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0453082A1 (fr) 1990-03-09 1991-10-23 Hybritech Incorporated Composés trifonctionnels similaires à des anticorps comme agent diagnostique et thérapeutique combiné
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
US7521056B2 (en) 2005-04-06 2009-04-21 Ibc Pharmaceuticals, Inc. Stably tethered structures of defined compositions with multiple functions or binding specificities
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2009089004A1 (fr) 2008-01-07 2009-07-16 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2015103072A1 (fr) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs d'immunoglobuline en tandem et leurs utilisations
WO2019157527A2 (fr) * 2018-02-12 2019-08-15 The Scripps Research Institute Méthodes associées à la maladie de parkinson et aux synucléinopathies
WO2020010273A1 (fr) * 2018-07-03 2020-01-09 University Of Miami Compositions et méthodes pour le traitement de maladies ou de troubles liés aux inflammasomes
US20200181578A1 (en) 2018-10-09 2020-06-11 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
US11015210B2 (en) 2013-03-14 2021-05-25 The Trustees Of The University Of Pennsylvania Constructs and methods for delivering molecules via viral vectors with blunted innate immune responses
CN114316057B (zh) * 2022-03-14 2022-05-10 深圳市人民医院 一种靶向线粒体外膜转位因子复合体tom20亚基的纳米抗体及其应用
WO2022180242A2 (fr) * 2021-02-26 2022-09-01 Forschungsverbund Berlin E.V. Absorption cellulaire de grandes biomolécules permise par des additifs peptidiques de pénétration cellulaire réactifs à la surface cellulaire
CN116178558A (zh) * 2023-03-28 2023-05-30 山西纳安生物科技股份有限公司 靶向组织因子的纳米抗体及其制备方法和应用
WO2023246623A1 (fr) * 2022-06-22 2023-12-28 复旦大学 Nanocorps et conjugué nanocorps-médicament ciblant cd73, procédé de préparation correspondant et utilisation associée
WO2024112252A1 (fr) * 2022-11-23 2024-05-30 Key2Brain Ab Anticorps vhh et utilisations associées

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0871490B1 (fr) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Segments de liaison hydrazone ramifies
WO2003076567A2 (fr) 2002-03-05 2003-09-18 Eli Lilly And Company Proteines hybrides g-csf heterologues
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (fr) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
SG11202009787VA (en) * 2018-04-26 2020-11-27 Paean Biotechnology Inc Modified mitochondria and use thereof
US20230372529A1 (en) * 2020-10-22 2023-11-23 Paean Biotechnology Inc. Mitochondria comprising anticancer drug and use thereof
CN114949236B (zh) 2021-02-22 2024-09-06 中国科学院上海药物研究所 二糖连接子、二糖-小分子药物偶联物以及糖链定点抗体-药物偶联物，其制备方法及用途
EP4489792A1 (fr) 2022-03-11 2025-01-15 Firefly Bio, Inc. Lieurs à base de phényl maléimide

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
EP0453082A1 (fr) 1990-03-09 1991-10-23 Hybritech Incorporated Composés trifonctionnels similaires à des anticorps comme agent diagnostique et thérapeutique combiné
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7521056B2 (en) 2005-04-06 2009-04-21 Ibc Pharmaceuticals, Inc. Stably tethered structures of defined compositions with multiple functions or binding specificities
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
WO2009089004A1 (fr) 2008-01-07 2009-07-16 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US11015210B2 (en) 2013-03-14 2021-05-25 The Trustees Of The University Of Pennsylvania Constructs and methods for delivering molecules via viral vectors with blunted innate immune responses
WO2015103072A1 (fr) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs d'immunoglobuline en tandem et leurs utilisations
WO2019157527A2 (fr) * 2018-02-12 2019-08-15 The Scripps Research Institute Méthodes associées à la maladie de parkinson et aux synucléinopathies
WO2020010273A1 (fr) * 2018-07-03 2020-01-09 University Of Miami Compositions et méthodes pour le traitement de maladies ou de troubles liés aux inflammasomes
US20200181578A1 (en) 2018-10-09 2020-06-11 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
WO2022180242A2 (fr) * 2021-02-26 2022-09-01 Forschungsverbund Berlin E.V. Absorption cellulaire de grandes biomolécules permise par des additifs peptidiques de pénétration cellulaire réactifs à la surface cellulaire
CN114316057B (zh) * 2022-03-14 2022-05-10 深圳市人民医院 一种靶向线粒体外膜转位因子复合体tom20亚基的纳米抗体及其应用
WO2023246623A1 (fr) * 2022-06-22 2023-12-28 复旦大学 Nanocorps et conjugué nanocorps-médicament ciblant cd73, procédé de préparation correspondant et utilisation associée
WO2024112252A1 (fr) * 2022-11-23 2024-05-30 Key2Brain Ab Anticorps vhh et utilisations associées
CN116178558A (zh) * 2023-03-28 2023-05-30 山西纳安生物科技股份有限公司 靶向组织因子的纳米抗体及其制备方法和应用

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", vol. 51, 2005, LIPPINCOTT WILLIAMS & WILKINS
"Uniprot", Database accession no. Q15388
AMORIM JA ET AL., NATURE REVIEWS ENDOCRINOLOGY, vol. 18, 2022, pages 243 - 258
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83
CARLRING ET AL., PLOS ONE, vol. 6, 2011, pages 22533
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
COLOMAMORRISON, NATURE BIOTECHNOL, vol. 15, 1997, pages 159 - 163
COLOMAMORRISON, NATURE BIOTECHNOL., vol. 15, 1997, pages 159 - 163
DOMENGERGRIMM, HUMAN MOLECULAR GENETICS, vol. 28, 2019, pages 1 - 12
DOPPALAPUDI ET AL., PROC. NATL. ACAD. SCI., vol. 107, 2010, pages 22611 - 22616
FREJD ET AL., EXP MOL MED., vol. 49, no. 3, 2017, pages 306
GOSSEN ET AL., SCIENCE, vol. 268, 1995, pages 1766 - 1769
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 - 5374
GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44
HARVEY ET AL., CURR. OPIN. CHEM. BIOL., vol. 2, 1998, pages 512 - 518
HOLLINGER ET AL., PROC. NATL. ACAD. SCI., vol. 110, 2013, pages 5145 - 5150
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553
LABRIJN ET AL., NATURE PROTOCOLS, vol. 9, 2014, pages 2450 - 2463
LAFLEUR ET AL., MABS, vol. 5, 2013, pages 208 - 218
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
LIU ET AL., CNS NEUROSCI THER., vol. 27, no. 7, July 2021 (2021-07-01), pages 733 - 742
MCCARTY ET AL., GENE THERAPY, vol. 16, 2001, pages 1248 - 54
MERCHANT ET AL., NATURE BIOTECHNOL., vol. 16, 1998, pages 677 - 681
MILER ET AL., J. IMMUNOL., vol. 170, 2003, pages 4854 - 4861
MILSTEINCUELLO, NATURE, vol. 305, 1983, pages 537 - 540
MOORE ET AL., BLOOD, vol. 117, 2011, pages 454 - 451
NUTTALL S D ET AL: "Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70", EUROPEAN JOURNAL OF BIOCHEMISTRY, PUBLISHED BY SPRINGER-VERLAG ON BEHALF OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES, HOBOKEN, USA, vol. 270, no. 17, 1 September 2003 (2003-09-01), pages 3543 - 3554, XP003013540, ISSN: 0014-2956, DOI: 10.1046/J.1432-1033.2003.03737.X *
PARDON, E. ET AL.: "A general protocol for the generation of Nanobodies for structural biology", NAT. PROTOC., vol. 9, 2014, pages 674 - 693, XP037547597, DOI: 10.1038/nprot.2014.039
PLUCKTHUN ET AL., ANN. REV. OF PHARMACOLOGY AND TOXICOLOGY, vol. 55, 2015, pages 489 - 511
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
SCHNEIDER ANSELM F L ET AL: "Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives", NATURE CHEMISTRY, NATURE PUBLISHING GROUP UK, LONDON, vol. 13, no. 6, 15 April 2021 (2021-04-15), pages 530 - 539, XP037470253, ISSN: 1755-4330, [retrieved on 20210415], DOI: 10.1038/S41557-021-00661-X *
SRIVASTAVA S., GENES, vol. 8, no. 12, 19 December 2017 (2017-12-19), pages 398
STAERZ ET AL., NATURE, vol. 314, 1985, pages 628 - 631
STAERZBEVAN, PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 1453 - 1457
TODOROVSKA ET AL., J. IMMUNOL. METHODS, vol. 248, 2001, pages 47 - 66
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
TUTT ET AL., J., vol. 147, 1991, pages 60 - 69
WOZNIAK-KNOPP ET AL., PROTEIN ENG. DES. SEL., vol. 23, 2010, pages 289 - 297
Y. A. MEDVEDEVA ET AL., BIOINFORMATICS-TRENDS AND METHODOLOGIES, vol. 449-472, 2011, pages 40
YIN ET AL., MABS, vol. 4, 2012, pages 217 - 22548
ZHUKOVSKY ET AL., BLOOD, vol. 122, 2013, pages 5116
ZIMMERMANN ET AL.: "Generation of synthetic nanobodies against delicate proteins", NAT. PROTOC., vol. 15, 2020, pages 1707 - 1741, XP037111835, DOI: 10.1038/s41596-020-0304-x

Also Published As

Publication number Publication date
WO2026042013A1 (fr) 2026-02-26

Similar Documents

Publication Publication Date Title
JP7577435B2 (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
CN111356701B (zh) 抗α-突触核蛋白抗体及其用途
US10865247B2 (en) Anti-human CD69 antibody, and use thereof for medical purposes
JP2018500025A (ja) ５ｔ４及びｃｄ３に対する３つの結合ドメインを含む融合タンパク質
CN103429619A (zh) 双特异性和单特异性、不对称抗体和其制备方法
MX2014009864A (es) Polipeptidos de union a cx3cr1.
EA035480B1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1 и их применения
JP7818828B2 (ja) 特異的結合分子
CN111886251A (zh) 抗a-syn/igf1r的双特异性抗体及其用途
US20240400716A1 (en) Molecules that bind to prostate specific membrane antigen (psma) polypeptides
JP2023120385A (ja) ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10906973B2 (en) Antibody variants transmigrating the blood-brain barrier and uses thereof
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
JP2023113599A (ja) α－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途
CN120303299A (zh) 转铁蛋白受体结合蛋白
US20230212272A1 (en) Isolated antigen binding protein and use thereof
KR20220075411A (ko) 글리보 - 계열 글리칸과 특이적으로 결합하는 단일 도메인 항체
JP7774063B2 (ja) メソテリンポリペプチドに結合する分子
JP2025537215A (ja) Ｇｉｐｒ結合タンパク質及びその使用
TW202330601A (zh) ＴｆＲ抗原結合蛋白及其用途
US20240415884A1 (en) Molecules that bind to cd276 polypeptides
HK40118215A (zh) 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子
WO2023011650A1 (fr) Anticorps multispécifique et son utilisation
JP2026504407A (ja) フォリスタチンポリペプチドに結合する分子
TW202328194A (zh) Ｌｉｌｒｂ２特異性單株抗體及其使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25765043

Country of ref document: EP

Kind code of ref document: A1